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INTRODUCTION
Hospital infections are caused by several microorganisms, being of great relevance the ones caused by bacteria. Some of these represent higher risk for the patient due to a reduced sensibility profi le to antimicrobial agents, as observed in glucose non-fermenting Gramnegative bacilli. In this group, Pseudomonas aeruginosa, followed by Acinetobacter baumannii are bacteria largely isolated in hospitals worldwide, being associated to high morbidity and mortality rates in seriously ill patients. 13 P. aeruginosa and A. baumannii have become increasingly resistant to broad-spectrum cephalosporins used in the hospital setting leading to the use of more powerful β-lactam antibiotics, as the carbapenems. 13, 15 Currently, these agents are important options to treat nosocomial infections due to their high affi nity for type 2 (PBP2) penicillin-binding proteins with, stability to many β-lactamases, including broad-spectrum (ESBL) and chromosomal (AmpC), besides showing excellent permeability through bacterial outer membrane. 23 Wide use of carbapenems in the hospital environment can cause more selective pressure on hospital microbiota, thus enhancing the subpopulation of microorganism with decreased sensibility or resistance to these antibiotics. Currently, bacterial samples of P. aeruginosa and A. baumannii resistant to most antimicrobial agents and sensitive only to polymyxin B have been isolated in most of the Brazilian hospitals. 5, 13 Resistance to carbapenems are thought to result from the production of Ambler class D and B β-lactamases, also refered to as metallo-beta-lactamases (MBL). Additionally, the production of these enzymes has commonly been responsible for the resistance phenotype to these β-lactams. 4, 21 Due to the potential relevance of the evolution of microbial resistance, the objective of this study was to investigate the prevalence of P. aeruginosa and A. baumannii resistant to carbapenems at the Santa Isabel Hospital in Blumenau, Santa Catarina state, Brazil.
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METHODS
All positive cultures for P. aeruginosa and A. baumannii resistant to carbapenems during the study period of January 2004 to December 2008 were included. Blood, urine, tracheal aspirate, washed bronchi alveolar, sputum, purulent wound, skin ulcers, and catheter tip samples collected from patients admitted to all units (ICU and other yards) were eligible. Data for bacterial identifi cation and sensitivity tests were obtained from the records of the Hospital Infection Control Commission (HICC). Samples were processed at the local microbiology laboratory.
Strains of P. aeruginosa were isolated on chocolate agar, blood agar and MacConkey agar based on colony morphology, oxidase positive test, and glucose non-fermenting kit (Probac).
Strains of A. baumannii were isolated on chocolate agar, blood agar and MacConkey agar based on colony morphology, negative oxidase test, and glucose non-fermenting kit (Probac).
For the sensitivity tests before placing the discs, MuellerHinton plates were inoculated with swabs immersed in the inoculation fi nal solution and smeared on the entire plate surface. Afterwards, the plates were inverted and incubated at 35 ± 2º C for 20 to 24 hours. The sensitivity was investigated using the Kirby-Bauer method for reading the disc diffusion, according to the Clinical and Laboratory Standards Institute criteria. 3 Annual resistance rates of each microorganism during the period of study were tested by the Fischer's exact test. 18 The pvalue for signifi cance was 0.05. Data analysis was performed with STATISTICA software, version 6. 19 
RESULTS
During the studied period 228 strains of P. aeruginosa and 140 strains of A. baumannii were isolated. In Brazil, the fi rst report of acquired MBL was in 1997, in a sample with P. aeruginosa, reported as SPM-1 variant at the São Paulo Hospital/UNIFESP. In 1998, in the same hospital, samples of Acinetobacter spp with resistance or reduced sensitivity to carbapenems were isolated. Out of those, 54% (40/73) were IMP-1 producers. In 2003, a sample of A. baumannii presenting IMP variant was isolated which was resistant to imipenem, meropenem and broad-spectrum cephalosporins. 6, 20, 21 Resistance of P. aerugionsa and A. baumannii to Carbapenems may result from changes in the penicillin-binding proteins and porins. Since carbapenems enter the bacterium through the porins, one could postulate that porins changes could be involved in the resistance to these antibiotics. 10, 12, 14 Effl ux pumps are a unique resistance mechanism against different classes of antimicrobials. AdeABC effl ux pump, characterized in A. baumannii, together with the over-expression oxacilinases can result in resistance to carbapenems. 14 In P. aeruginosa, the MexA-MexB-OprM effl ux pump is responsible for antimicrobial transport to the external side of the bacterial cell. 9, 11 At Saint Joseph Martin Hospital in Buenos Aires from 1998 to 2001, Rodriguez et al., reported 60% of Acinetobacter spp resistance to imipenem. Furthermore, P. aeruginosa showed an increasing resistance to imipenem from 15.4% to 68%.
A Latin America multicenter study, the SENTRY -Antimicrobial Surveillance Program -reported in 2001 Acinetobacter spp. resistance rates to imipenem of 16.7% and to meropenem of 18.17%. P. aeruginosa presented resistance of 37.8% to imipenem and 35.6% to meropenem. 16, 17 The data obtained showed a signifi cant increase of A. baumannii carbapenems resistance from 2005, whereas P. aeruginosa did not present statistically signifi cant difference over the years. Molecular studies are essential to unfold resistance mechanisms, mainly associated to A. baumanii. Likewise, they will be useful to evaluate a possible cloned dissemination in the hospital environment.
CONCLUSION
New bacterial resistance patterns have emerged, and the gathering of different enzymes in different bacterial species shows the real potential for dissemination of these genetic elements and causes great concern.
The data presented showed high rates of Pseudomonas aeruginosa and Acinetobacter baumannii resistant to carbapenems, reducing the availability of effective agents. The fi ght against these microorganisms in hospitals can be accomplished through the constant presence of the hospital infection control committee, recognizing the local microbiota and having protocols for a rational use of antimicrobials.
